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Abstract
Pseudomonas aeruginosa, a versatile Gram- negative pathogen that can cause a wide range of infections, is the most common 
causative agent in cases of bacterial keratitis associated with contact- lens use. Corneal infections with P. aeruginosa often have 
poor clinical outcomes and can result in long and costly treatments. During the infection process, the pathogen exploits its large 
genome, encoding complex regulatory networks and a wide range of virulence factors, including motility and the secretion of 
various proteases and toxins. Although antibiotic resistance levels in the UK are low, higher levels have been seen in some other 
countries. In the face of increasing antibiotic resistance, alternative therapeutic approaches such as antivirulence strategies 
and phage therapy are being developed. There is increasing evidence to suggest that keratitis infections are associated with a 
phylogenetic subgroup of P. aeruginosa isolates carrying the gene encoding the potent cytotoxin exotoxin U, one of two mutu-
ally exclusive exotoxins secreted via the type III secretion system. The mechanisms behind this association are unclear, but 
understanding the genetic differences that predispose P. aeruginosa to cause corneal infections may allow for the development 
of targeted and more effective future treatments to reduce the morbidity of P. aeruginosa keratitis. In order to minimize the risk 
of severe P. aeruginosa eye infections, a wide range of contact- lens disinfection solutions are available. Constant exposure to 
biocides at a range of concentrations, from sub- inhibitory to inhibitory, could contribute to the development of resistance to 
both antibiotics and disinfectants.
MIcRobIal kERatItIs
Keratitis is an ophthalmological disease in which the cornea 
becomes inflamed and it can result in partial or total loss of 
vision in severe cases. The disease can result from microbial 
infection (e.g. bacteria, fungi, viruses or protozoans) or from 
non- infectious damage, such as that caused by eye trauma 
or exposure to chemicals or ultraviolet light [1]. Microbial 
keratitis, however, usually involves ulceration of the cornea 
with subsequent neovascularization, scarring and loss of 
vision. The aetiology and occurrence of microbial keratitis 
varies geographically, depending largely on climate and 
level of industrialization. After cataracts, bacterial keratitis 
is the second- largest cause of legal blindness worldwide [2]. 
Keratitis also incurs significant annual costs to healthcare 
providers around the world. Data from the USA estimated 
that 988 000 visits were made to doctors’ surgeries, outpa-
tient clinics and hospital emergency departments in 2010 
for keratitis and contact- lens- related illnesses. In total, 
these visits were estimated to cost $174.9 million and over 
250 000 h of clinician time [1]. Quantification of the costs 
incurred by admission and treatment of keratitis patients by 
the National Health Service (NHS) in the UK was carried out 
over a period of 12 months (January–December 2013) using 
data collected from 101 patients with microbial keratitis 
attending a tertiary referral centre. The total calculated cost 
of admission for all patients was £382 473, with the total 
income generated calculated as £267 028, giving a deficit of 
£115 445 per annum for this centre alone [3]. Length of stay 
was determined to be the most critical factor in increasing 
the cost deficit, with surgical intervention also driving up 
the cost of care.
In cases of bacterial keratitis, the most common causative 
agents are Staphylococcus aureus, Pseudomonas aeruginosa, 
coagulase negative Staphylococcus, Streptococcus spp. and 
Enterobacteriaceae [4]. In cases associated with contact- lens 
use P. aeruginosa is consistently the most commonly isolated 
microbe from corneal scrapings [5–7].
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contact-lens-associated microbial keratitis
For more than 30 years, the use of contact lenses has been 
acknowledged as a predisposing factor in the development of 
microbial keratitis [8], with the use of contact lenses increasing 
at an annual rate of 5–15 % [9]. The contribution of individual 
factors, however, including lens material, duration of use, 
cleaning and hygiene, and lens quality must also be taken 
into consideration. Most recent figures estimate worldwide 
contact- lens use at 140 million patients, with 10–12 % of the 
population in the USA and UK using contact lenses regularly 
for vision correction [9]. Annually, contact- lens- associated 
microbial keratitis is estimated to affect 1 in 2500 ‘daily use’ 
patients and 1 in 500 ‘overnight use’ patients [10–13]. Whilst 
it is not the only causative agent of bacterial keratitis associ-
ated with contact- lens use, P. aeruginosa is responsible for the 
majority of corneal ulcers associated with lens wear [8, 14].
P. aeruginosa
P. aeruginosa is a versatile Gram- negative bacterium that can 
occupy a wide range of environmental niches but also acts 
as an opportunistic pathogen, causing numerous different 
kinds of infection [15]. P. aeruginosa is an important pathogen 
in worldwide healthcare and is included in the ESKAPE 
pathogen group commonly associated with concerning 
increases in antimicrobial resistance (AMR) [16]. It has also 
recently been identified by the World Health Organization as 
one of the top three priority 1 pathogens urgently requiring 
development of new antibiotics for effective treatment of 
infection [17]. P. aeruginosa is responsible for approximately 
10 % of nosocomial infections in the European Union [18]. It 
frequently causes infections in severely immunocompromised 
individuals (such as cancer patients) or neonates, people 
with severe burns or wounds, patients subjected to invasive 
procedures (such as the use of catheters or ventilators) or 
individuals with debilitating disorders such as cystic fibrosis. 
It is also the leading cause of sight- threatening corneal disease 
in otherwise healthy patients who use contact lenses [19, 20]. 
The versatility of P. aeruginosa and its ability to cause a wide 
range of human diseases is attributed to its large genome [21], 
which confers metabolic flexibility and adaptability.
Variation in the pathogenicity of P. aeruginosa is driven 
largely by diversity among the global population. Not only is 
the P. aeruginosa genome large (generally >6 Mbp), but it is 
composed of a core genome of well- conserved genes carried 
by all strains interspersed with regions of genomic plasticity 
(RGP) at specific sites on the genome, which contain acces-
sory genes [22]. These accessory genome regions can vary 
significantly between strains and contribute to pathogenicity. 
A recent study using a dataset from 1311 strains reported 
a pangenome (total genomic content of the population) 
of 54 272 genes, with only 665 representing the strict core 
genome (present in all strains). However, 26 420 of these 
genes were assigned to the ‘flexible genome’ (present in some 
strains but not others), with 27 187 being unique (present in 
only one strain) [23]. The P. aeruginosa genome has a high 
G+C content (approximately 67%), with genes acquired from 
other species, often found as part of the accessory genome, 
having a notably lower G+C content. Phylogenetic analyses 
based on the core genomes of P. aeruginosa isolates has shown 
that the vast majority of isolates can be sub- divided into two 
major phylogenetic subgroups: group 1, which includes the 
commonly studied strains PAO1, LESB58 and DK2; and 
group 2, which includes strain PA14 [23].
P. aeruginosa virulence factors
Despite its status as an opportunistic pathogen that rarely 
causes infections in healthy individuals, P. aeruginosa genomes 
carry a multitude of virulence factors (Table 1) controlled by 
complex regulatory circuits [24] that are capable of acting in a 
combinatorial fashion to colonize and injure host tissue [25].
The vast and complicated global regulatory systems employed 
by P. aeruginosa play an important role in regulating viru-
lence during infection. Quorum- sensing (QS) systems have 
been shown to play a role in regulating the production of 
numerous virulence factors, including pyocyanin, hydrogen 
cyanide, elastases A and B, and alkaline protease [24]. P. 
aeruginosa utilizes four distinct QS systems in order to 
regulate gene expression [26]. Two acylhomoserine lactone 
(AHL) systems, las and rhl, rely on feedback loops mediated 
by N-(3- oxododecanoyl)- homoserine lactone (3O- C12- HSL) 
and N- butyrylhomoserine lactone (C4- HSL), respectively. 
The quinolone- mediated PQS system relies on the compound 
2- heptyl-3- hydroxy-4- quinolone. The IQS system is capable 
of integrating stress cues from the environment with the QS 
network via secretion and uptake of the molecule 2-(2- hyd
roxyphenyl)- thiazole-4- carbaldehyde [27]. Genes regulated 
by AHL QS systems respond with varying specificity to 
3O- C12- HSL and C4- HSL, with some responding equally 
well to both signals. The genes regulated by las and rhl make 
up a large portion of the average P. aeruginosa genome 
(~10 %) [28]. There is evidence that both the PQS and IQS 
systems interact with the AHL QS systems to form a complex 
and multi- layered signalling system that regulates virulence 
factors in P. aeruginosa [27].
Generally, P. aeruginosa isolates can be sorted into two groups 
(pathotypes) based on mode of toxicity via secreted toxins 
of the type III secretion system (T3SS); those which secrete 
exotoxin S (ExoS) and act to cause invasive infections, and 
those which secrete exotoxin U (ExoU) and cause acute cyto-
toxicity in host cells [29]. For the most part, those genomes 
encoding exoS fall into phylogenetic group 1 and those 
encoding exoU are in phylogenetic group 2. Most isolates have 
a copy of only one of these two genes although presence of 
the gene does not guarantee secretion in vitro [30]. Strains of 
P. aeruginosa carrying both or neither of the exoS and exoU 
genes are far less common than those containing one or the 
other and are often considered atypical [31].
ExoS acts with dual functional enzymatic activity to affect 
two host Ras- related GTP binding proteins. Host cell Ras 
is inactivated through ADP ribosylation, whilst GTPase 
activating protein (GAP) activity at the N- terminus of ExoS 
inactivates Rho proteins [32]. Meanwhile, ExoU has acute 
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Table 1. Important P. aeruginosa virulence factors and their role in pathogenicity
Virulence factor Secretion system Host target Role in pathogenicity
Alginate Extracellular polysaccharide. Overproduced in mucoid strains often isolated from chronic 
pulmonary infections. Participates in the production of biofilms. Treatment with imipenem 
has been shown to induce expression of alginate and leads to thickening of biofilms [89]. 
Other polysaccharides (Pel and Psl) can also contribute to biofilm formation [90].
Alkaline protease Type I Complement proteins 50.4 kDa zinc- dependent metalloprotease. Type I secretion of alkaline protease requires the 
products of aprD, aprE and aprF. aprI is believed to cause intracellular alkaline protease 
inhibition in order to avoid intracellular toxicity [91].
Elastase A
(LasA)
Type II Matrix proteins 20 kDa metallopeptidase, also known as staphylolysin is secreted as a proenzyme before 
becoming activated extracellularly. LasA acts with restricted specificity, predominantly at 
glycine- glycine peptide bonds, but also increases the elastinolytic activity of LasB [92].
Elastase B
(LasB)
Type II Matrix proteins 33 kDa zinc- metalloprotease derived from lasB- encoded 52 kDa precursor protein, which 
undergoes autocatalytic cleavage. The 18 kDa propeptide remains associated with the 
mature protease to prevent premature proteolytic activity of the enzyme whilst in the cell’s 
periplasm [91].
ExoA Type II Cell structure 66 kDa protein member of the AB toxin family formed of two domains. Domain A 
providies enzymatic activity and domain B acts as a cell binding subunit. In host cell 
cytosol, elongation factor 2 undergoes catalytic ADP- ribosylation by ExoA which inhibits 
protein synthesis and induces apoptosis [93].
ExoS Type III Cell structure 49 kDa bi- functional cytotoxin. The N- terminal encodes a RhoGAP domain and the C- 
terminal an ADP- ribosylation domain [94].
ExoT Type III Cell structure Bifunctional toxin. GTP- ase activating protein activity and ADP ribosyl transferase activity. 
Ribosylates CT10 regulator of kinase (CRK) I and CRKII adaptor proteins [95].
ExoU Type III Cell structure 74 kDa hydrophilic protein with broad- range lipase activity. Injected into the host cell via 
T3SS leads to rapid damage to the cell membrane and organelles with cell lysis [33].
ExoY Type III Cell structure Secreted adenyl cyclase. Increases concentration of intracellular cAMP in host cells, with 
disruption of actin cytoskeleton and increased endothelial permeability [95].
Flagella Cell surface Major surface adhesion. Elicits strong NFκB- mediated inflammatory response via 
signalling through toll- like receptor (TLR) 5 and a caspase-1- mediated response through 
Nod- like receptor, Ipaf. Provides bacterium with swimming motility in liquid [96].
Hydrogen 
cyanide
Mitochondria Effects of hydrogen cyanide (HCN) on host cells varies depending on cell type and 
oxidative stress; leading to either apoptosis or necrosis. HCN acts to increase generation of 
cellular reactive oxygen species in host cells. HCN is produced from glycine in a reaction 




Type I Macrophages Catalyses the exchange of phosphate groups between nucleoside diphosphates. NDK 
induces expression of IL-1α and IL-1β in combination with signals initiated by bacterial 
flagellin [98].
Phospholipase C Type II Cell membranes Haemolytic phospholipase C cause vascular permeability, end organ damage, and death 
when administered to mice in high doses. Production is induced by phosphate starvation 
and may act in phosphate- scavenging pathways in Gram- negative infections in humans in 
which circulating phosphate levels are sub- optimal for bacterial growth [99].
Protease IV Type II Complement proteins Lysine- specific endoprotease. Protease IV is capable of inactivating a range of host defences 
including fibrinogen, plasminogen, immunoglobulin G, and complement proteins○ 
C1q and C3[100]. Initially protease IV is expressed in the cytoplasm as a 48 kDa pre- 
proenzyme, then cleaved to a 45 kDa proenzyme, and finally cleaved to a 26 kDa mature 
protease upon secretion. Transcription of the piv gene which encodes protease IV is 




Type II Structural proteins 18.5 kDa protein capable of cleaving type I and IV collagens. Exists in an inactive form in 
the cytoplasm and periplasm but becomes active after secretion. PASP has been shown to 
induce PMN migration in the corneal stroma [42].
Pyocyanin Widespread toxicity Redox- active phenazine inhibits host cell respiration, ciliary function, and epidermal 
growth; disrupts calcium homeostasis and induces apoptosis in neutrophils. Production 
is partly controlled by oxidative stress response regulator, OxyR and is thought to play a 
protective role against phagocytic cells [102].
Continued
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cytolytic activity, which involves targeting of the host cell 
membrane via phospholipase [33]. Lysis mediated by ExoU is 
rapid and has been shown to affect mammalian macrophages, 
epithelial cells and fibroblasts in vitro [34–37]. In a previous 
study utilizing a small panel of isolates it was concluded 
that there was no significant association between carriage 
of either exoS or exoU and isolates collected from keratitis 
cases [38]. However, in later studies it has been shown that 
a higher proportion of keratitis infections are caused by 
isolates carrying the exoU gene encoding cytotoxic ExoU, 
when compared to other kinds of infections [39–41]. In the 
large- scale Steroids for Corneal Ulcers Trial (SCUT) there was 
shown to be a significant difference in mean infiltrate/scar 
sizes between patients infected with invasive (4.66 mm) and 
cytotoxic (3.61 mm) P. aeruginosa. Further analysis of patients 
in the trial also showed differences in clinical outcomes 
3 months after treatment; patients infected with genotypically 
invasive strains (exoS- positive) were shown to present with 
better visual acuity than those patients infected with cyto-
toxic strains (exoU- positive) but showed less improvement 
in visual acuity at 3 months. The trial’s main purpose was 
to investigate the potential clinical use of adjunctive topical 
corticosteroids for the treatment of bacterial keratitis. Further 
investigation revealed that the corticosteroid treatment had 
differential effects on ulcers caused by cytotoxic and invasive 
P. aeruginosa [31].
Alongside exotoxins, P. aeruginosa produces a range of 
proteases (Table 1), which cause damage to host cells and 
aid in immune evasion. Protease IV and P. aeruginosa small 
protease (PASP) have been shown to be present and well 
conserved in the genomes of several isolates from varying 
clinical sources, with PASP also being identified as a keratitis- 
associated virulence factor [42–44].
A study of P. aeruginosa strains isolated from cases of keratitis 
infections in the UK, identified the dominant serotypes as O1 
and O11 in addition to common genetic features that may 
confer an advantage to P. aeruginosa during an ocular infec-
tion [39]. There has been shown to be a significant correlation 
between serotype O11 and carriage of the exoU gene (Table 1) 
[30, 39, 45]. Twitching motility, attributed to the type IV pili 
(Table 1), is implicated in corneal virulence; mutants of P. 
aeruginosa that do not exhibit twitching motility have been 
shown to have a reduced ability to colonize the cornea of 
mice vs. strains with unaffected twitching motility [46]. In 
a further study of UK keratitis P. aeruginosa, a large number 
of isolates were shown to carry an uncommon group II pilA 
gene, suggesting that carriage of particular alleles of pilA 
may be advantageous during keratitis infections [40]. Some 
of these and other virulence factors have been associated with 
poorer clinical outcomes in patients [47].
P. aeruginosa keratitis – host response
Corneal infection caused by P. aeruginosa has been shown 
to be associated with significantly worse visual acuities than 
infection with other bacterial pathogens [48]. A major hall-
mark of P. aeruginosa keratitis is presentation of a ring abscess 
(Fig. 1), in which a ring- shaped accumulation of polymor-
phonuclear neutrophils (PMN) surround the central lesion; 
serrated and satellite lesions are also associated with P. aerugi-
nosa keratitis, although the former can appear at first glance to 
be as a result of a fungal infection [47]. Much of the damage 
caused to the eye during microbial keratitis is due to the 
overstimulation of the host immune system by foreign cells 
in the eye. The cornea exhibits a certain amount of immune 
privilege; there must still be a system in place by which 
the eye can detect and defend against potentially harmful 
microbes. In the cornea, macrophages and dendritic cells play 
an important role in initiating the innate immune response. 
The expression of pattern recognition receptors (PRRs), 
such as toll- like receptors (TLRs) and NOD- like receptors 
Virulence factor Secretion system Host target Role in pathogenicity
Pyoverdine Cellular iron Siderphore. Little free iron is available in the host environment so pyoverdine acts to 
sequester iron from host depots [103]. Iron- bound pyoverdine acts as a signalling molecule 
and interacts with Pseudomonas cell receptor FpvA, causing upregulation of exotoxin A, 
endoprotease and pyoverdine itself [104].
Rhamnolipid Surfactant. Participates in the maintenance of uninhabited channels surrounding biofilm 
communities which serve to provide nutrients and oxygen to the colonies of bacteria [105]. 
Biofilms can form on implants and on dead or living tissue and are inherently difficult 





Cell surface P. aeruginosa utilizes three proteins for translocation; PopB, PopD and PcrV. All three 
proteins are required for pore formation but PopB also plays a role in P. aeruginosa 
pathogenicity independently from effector proteins. PcrV is located at the end of the T3SS 
needle complex and acts as a platform for PopB and PopD to form the translocation pore 
[95].
Type IV pili Cell surface Major surface adhesion molecules providing twitching motility over moist surfaces. Signal 
transduction mechanism requires attachment of type IV pili to solid surface, retraction of 
pilus, and signal transduction through the Chp chemo- sensory system (activates cAMP 
production and transcription of hundreds of genes, including key virulence factors) [106].
Table 1. Continued
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(nucleotide- binding oligomerization domains; NLRs), allows 
host recognition of conserved pathogen structures known 
as pathogen- associated molecular patterns (PAMPs). Activa-
tion of PRRs results in production of a cascade of inflamma-
tory cytokines such as IL-1, IL-6 and IL-8 via NF-κB [49]. 
TLR4 and TLR5 on macrophages recognize the flagellin 
and lipopolysaccharide (LPS) of P. aeruginosa and initiate a 
myeloid differentiation primary response gene 88 (MyD88) 
mediated pro- inflammatory pathway [50]. Pre- treatment 
with flagellin has been shown to act protectively in mouse 
models of keratitis infection by dampening the upregulation 
of IL-24, which suppresses early mucosal immune responses 
and leads to increased disease severity [51]. Stimulation of the 
immune inflammatory response leads to corneal damage and 
subsequent scarring and vision loss. Prolonged recruitment 
of PMN and other white blood cells [52] is associated with 
corneal scarring and there is evidence in mice that a reduction 
in the recruitment of PMN to the cornea leads to a signifi-
cant reduction in tissue damage [53]. It is unclear, however, 
whether a reduction in the PMN response is associated with 
greater tissue invasion and pathogen retention in the cornea.
As well as the initial inflammatory cascade, there are several 
factors protecting the eye as an integral part of the innate immune 
system. These include chemical compounds, which are always 
present in the tear fluid and aid in generalized protection from 
microbial pathogens. Iron is an essential nutrient for microbes 
and so lactoferrin present in the tear fluid sequesters iron away 
from any potential pathogens. Peptidoglycan in the bacterial cell 
wall can be cleaved by the enzyme lysozyme, and membrane 
lipids present in certain bacteria can be cleaved by secretory phos-
pholipase A2(70). Other factors are also produced by cells of the 
ocular surface upon detection of bacteria, including defensins, 
which create holes in bacterial cell membranes, and arachidonic 
acid metabolites, which can further help recruitment of white 
blood cells.
Because there are limits to the understanding of molecular 
and cellular reactions in the eye that can be achieved by the 
study of human subjects, in vitro cell line and in vivo animal 
models have been developed, albeit with limitations that 
reduce their relevance to human infections. To study the 
pathogenesis of contact- lens- associated microbial keratitis, 
contact- lens models have been developed in mice [54], rats 
[55, 56], rabbits [57] and guinea pigs [58]. The supply of 
contact lenses for such models is often limited, reducing the 
numbers available for experimentation. Models using larger 
animals, such as rabbits, often involve surgery on the subject 
to close the eyelid in order to hold the lens in place on the 
eye. In models using guinea pigs it was demonstrated that 
inflammatory events occurred in the eye but did not lead to 
the development of microbial keratitis [54].
Membrane- localized reporters were used in the mouse 
contact- lens model to investigate the cellular structural 
changes that occur in the cornea as a result of extended 
contact- lens use [54]. After 14 days of continuous wear, 
vesicles were observed in the external layers of the corneal 
epithelium. Keratocytes in the stroma were shown to have an 
altered morphology, with jagged edges, compared to smooth 
appearance of those in the controls. The presence of highly 
motile cells moving throughout the stroma was also observed 
as early as 5 days after the implementation of the contact 
lenses. As well as the cellular morphology changes observed 
following extended contact lens wear, there was also shown to 
be increased neutrophil recruitment into the corneal stroma 
associated with interleukin 1R (IL- 1R) and MyD88 [54]. 
Long- term, continuous contact- lens use is a known risk factor 
for complications in humans, so it is important to ascertain if 
behaviours such as removing contact lenses for a short period 
of time would be likely to reduce neutrophil recruitment and 
thus reduce the potential for damage to be caused to the eye 
by a prolonged inflammatory response.
antIbIotIc REsIstancE
Advice for the treatment of bacterial keratitis from The Royal 
College of Ophthalmologists states that initial treatment 
should be with a broad- spectrum antibiotic that is active 
against both Gram- positive and Gram- negative bacteria 
[59]. However, in recent years it has been observed that to 
improve clinical outcomes a more targeted treatment is often 
required [60]. It has been shown that there is a relationship 
between the MIC of the antimicrobial and the healing time 
of the corneal ulcer. The lower the MIC, the better the clinical 
outcome [60]. Rapid identification of the likely causative 
bacteria combined with clinical acumen enables selection 
of the appropriate antimicrobial. Isolation of the bacteria 
allows the MIC to be determined for selected and available 
antibiotics. In the UK, first- line treatment is generally with a 
topical fluoroquinolone such as ciprofloxacin, ofloxacin, levo-
floxacin or moxifloxacin. Prolonged use of aminoglycosides 
such as gentamicin results in host cell toxicity and potential 
damage to the corneal epithelium, which may prolong healing 
time [59]. In cases where first- line treatment is not optimum 
or fails, or if drug resistance is identified, either switching 
to an alternative antibiotic or combination therapy may be 
Fig. 1. P. aeruginosa keratitis. Note ring shaped abscess and hypopyon 
(presence of inflammatory cells in the anterior chamber of the eye).
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required. In cases where combination therapy is required it is 
important to ensure that additional antibiotic combinations 
provide additive or synergistic effects.
P. aeruginosa is considered a major global health concern due 
to increasing levels of resistance to disinfectants and anti-
biotics. Multidrug- resistant (MDR) strains of P. aeruginosa 
are responsible for approximately 13 % of P. aeruginosa infec-
tions (n=6700) and cause more than 400 deaths in the USA 
annually [61]. P. aeruginosa regularly forms biofilms during 
infection, which confers drastically increased resistance to 
antibiotics, even if the strains are susceptible when grown 
planktonically [62]. Antibiotics that are clinically useful, such 
as carbapenems, fluoroquinolones and aminoglycosides, have 
been shown to effectively kill P. aeruginosa in planktonic 
growth but can induce more severe biofilm production when 
the bacteria are exposed at sub- inhibitory concentrations [63]. 
As bacteria living in a biofilm community are often exposed to 
sub- inhibitory concentrations of antibiotics when treatments 
are administered, this may contribute to the exacerbation of 
chronic infections by increasing the robustness of existing 
biofilms or encouraging the spread of the infection. Much of 
the intrinsic resistance conferred to P. aeruginosa is due to 
low membrane permeability and a range of multidrug efflux 
pumps, particularly the MexAB- OprM and MexXY- OprM 
systems [64, 65].
In work carried out to investigate antibiotic susceptibility and 
effects of treatment in keratitis isolates, antibiotic resistance 
has been shown to be relatively uncommon. In 158 Pseu-
domonas spp. isolates collected from clinics in the UK, mean 
MIC90 for commonly used topical antibiotics were all equal to 
or lower than the systemic breakpoints (Table 2) [60]. A large- 
scale review was also carried out to determine the reported 
rates of resistance to those antibiotics most commonly used 
in the treatment of microbial keratitis (ciprofloxacin, β-lactam 
group cephalosporins and gentamicin) among bacterial 
isolates from microbial keratitis cases in Australia. It showed 
that rates of resistance in ocular isolates of P. aeruginosa 
and S. aureus were low [66]. Higher rates of resistance have 
been reported in the USA and India [66]. It is possible that 
increased resistance occurs in these countries as they impose 
fewer regulations on the use of antibiotics in livestock, which 
may contribute to increasing incidence of antibiotic resist-
ance in bacteria in environmental reservoirs, from which it is 
believed that many of the bacteria that infect eyes are derived. 
In India, there are also concerns about the availability of 
antibiotics without prescription (‘over the counter’) and their 
inappropriate prophylactic use, which may also contribute to 
increased antibiotic resistance [66]. In general, resistance to 
the most commonly used drugs in the treatment of microbial 
keratitis is uncommon in both P. aeruginosa and S. aureus.
Antibiotic resistance in P. aeruginosa is often conferred by 
mutations leading to, for example, up- regulation of resistance- 
related genes (efflux pumps, β-lactamases) or reduced entry 
(porins, such as OprD). However, mobile genetic elements 
(MGEs) are often associated with MDR strains of P. aerugi-
nosa, especially in hospital settings [67]. The three most 
commonly used antibiotic classes in the treatment of ocular 
infections are beta- lactams, aminoglycosides and fluroqui-
nolones, and genes conferring resistance to all antibiotics 
from all three of these classes have been shown to be trans-
missible by MGE between bacterial strains [67]. P. aeruginosa 
isolates from keratitis infections in India were shown to have 
additional resistance genes, including qacEΔ1, a quaternary 
ammonium compound (QAC) resistance gene [68]. Earlier 
research showed that MDR strains of P. aeruginosa sometimes 
carry qac resistance genes but that these genes do not always 
confer increased resistance to QACs, even in isolates with 
increased antibiotic resistance [69].
Treatment of microbial eye infections most commonly utilizes 
a combinatorial approach, with clinicians most commonly 
prescribing dual therapy targeting both Gram- negative and 
Gram- positive pathogens. This treatment usually consists of 
a β-lactam and an aminoglycoside as a first course of action 
upon the patient presenting to their health practitioner [66]. 
As such, the effects of combinatorial treatments against kera-
titis P. aeruginosa isolates have also been investigated. Meas-
uring the fractional inhibitory concentration (FIC) allowed 
classification of combinations of antibiotics as synergistic, 
additive or antagonistic. No consistent antagonistic effects 
were found, and the only synergistic effect was detected during 
combinatorial treatment with meropenem and ciprofloxacin. 
This is in comparison to treatment of S. aureus isolates, for 
which synergistic or additive effects were demonstrated for 
four combinations of antibiotics in 60–80 % of isolates [70].
Resistance to disinfectants and preservatives
Patient hygiene and compliance also plays a major role in 
the development of contact- lens- associated keratitis infec-
tions, and the importance of effective cleaning solutions for 
non- daily contact lenses cannot be understated. There are a 
wide range of commercially available contact lens disinfecting 
solutions, both branded and generic, that utilize different 
active ingredients (Table 3) in order to prevent microbial 
contamination of contact lenses.
QACs are among the most commonly used active ingredi-
ents in contact- lens disinfecting solutions, primarily chosen 
for their effectiveness and ease of use, but are also used in a 
range of household products including shampoo, sun creams 
and lotions, make- up remover and hand sanitizer [71]. 
Table 2. Mean MIC
90
 values for Pseudomonas spp. isolated in the UK 
from Kaye et al. [60] alongside systemic breakpoints taken from 
EUCAST guidelines [107]. Breakpoint data for Pseudomonas spp. and 
ofloxacin were not available in the EUCAST document






Ofloxacin Not available 1.5
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Traditionally, disinfection of contact lenses used hydrogen 
peroxide- based solutions that required two steps to be carried 
out by the user: disinfection using hydrogen peroxide, followed 
by neutralization of the active ingredient with a separate solu-
tion before applying the contact lens. Multipurpose ‘no rinse’ 
solutions (Table 3) have become increasingly popular with 
consumers due to ease of use. Many contact- lens practitioners 
and opticians tend to recommend solutions that are easier 
to use to maximize user compliance and therefore reduce 
the chance of infections and other contact- lens- associated 
complications. The method of use for no rinse multipurpose 
solutions, many of which are also ‘no rub’ (i.e. the contact 
lens does not need to be rubbed between the fingers in order 
to ensure removal of any possible attached microbes), means 
that micro- organisms, bacteria in particular, may be exposed 
to sub- inhibitory concentrations of the active ingredient 
for an extended period of time. This allows for selection of 
those remaining bacteria with increased MIC values and 
an increased likelihood of development of resistance to the 
disinfectant. Similarly it has also been shown that use of 
QACs can lead to increased fixation of novel genetic elements, 
which can lead to the acquisition and spread of resistance to 
antibiotics [72]. The qac family of genes (qacC, qacG, qacH 
and qacJ), named for their role in resistance to QACs, are 
found across several bacterial genera and have been shown 
to play a role in resistance to a range of cationic compounds, 
including intercalating dyes, diamidines and biguanides 
[73–75]. The proteins encoded by the qac genes are involved 
in low- specificity multidrug efflux pumps [75].
The antibacterial activities of five major multipurpose contact- 
lens disinfecting solutions were tested against P. aeruginosa 
PAO1 and methicillin- resistant S. aureus (MRSA) TCH1516 
using the Clinical and Laboratory Standards Institute (CLSI) 
broth microdilution method. The solutions that were most 
active were not the same for P. aeruginosa and S. aureus; Boston 
Simplus (Bausch and Lomb, USA) was the most antistaphylo-
coccal of the solutions, whilst Menicare GP (Menicon, Japan) 
was shown to have the highest antipseudomonal activity [76]. 
Further to this, the MIC for Boston Simplus against MRSA was 
1.5 % whereas the MIC for Menicare GP against P. aeruginosa 
was 23 %. All of the disinfecting solutions were shown to be 
more effective against MRSA than P. aeruginosa, and the same 
results were observed when MIC testing was repeated with 
three S. aureus and three P. aeruginosa clinical isolates [76]. 
When tested alone, the most effective preservative against P. 
aeruginosa was shown to be ethylenediaminetetraacetic acid 
(EDTA), with an MIC of 2500 p.pm (vs. 300 ppm against S. 
aureus), but EDTA was shown to act synergistically against 
P. aeruginosa with chlorhexidine gluconate (CHD). When 
combined, a solution containing 4 ppm CHD (~1/4 MIC) 
and 300 ppm EDTA (~1/8 MIC) was sufficient to eradicate P. 
aeruginosa, reducing bacterial numbers by >4 log10 in quan-
titative 2 h killing assays [76].
It has been suggested that constant exposure to biocides 
across domestic, healthcare and industrial environments at 
a range of concentrations, from sub- inhibitory to inhibitory, 
also contributes to the development of resistance to both 
antibiotics and disinfectants among bacterial populations 
[77]. However, there is conflicting evidence, which indicates 
that this type of co- adaptation to increased survival in the 
presence of both antibiotics and disinfectants is uncommon 
and of little clinical significance [78, 79].
FutuRE tREatMEnts and dEVElopMEnts
With growing concerns about the rise of antibiotic resistance 
in bacterial species, particularly in P. aeruginosa, the need 
for new or improved treatments for all manner of bacterial 
infections is greater than ever. Bacteriophages were first 
identified in the early twentieth century, but research into 
the potential therapeutic uses of phage did not start in earnest 
until the 1920s and was largely abandoned as a treatment 
option following the discovery of penicillin and the dawn of 
the antibiotic era. Driven by the emergence of MDR strains 
of pathogenic bacteria, research into phage therapy has expe-
rienced a resurgence in recent years. Phage have been shown 
to effectively kill bacteria and improve disease outcomes in 
a range of animal models and infections [80]. Of particular 
interest is the topical application of phage preparations for 
the treatment of keratitis. Fukuda et al. [81] infected the 
corneas of mice with a clinical P. aeruginosa strain via topical 
administration following damage to the cornea. Mice subse-
quently treated with KPP12 phage were shown to undergo a 
drastically less severe disease course than those mice treated 
Table 3. Commonly used, commercially available contact- lens 
disinfecting solutions and their active antimicrobial ingredients. 
Ingredients and information sourced from work by Lin et al. [76] and 












































*solutions used by Lin et al. [76].
+solutions used by Johnston et al. [108].
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with the vehicle (mock- treated). Histopathological examina-
tion of corneas from treated and mock- treated mice revealed 
structural differences within the eye following infection and 
subsequent treatment, with mock- treated mice suffering 
more severe structural damage. Further examination showed 
that bacteria were present in almost undetectable loads in 
treated mouse corneas, whereas P. aeruginosa was shown to 
be present in high numbers in the abscesses of mock- treated 
mice. The improvements in disease severity elicited by this 
phage treatment against severe P. aeruginosa keratitis infec-
tion show promise for the future of topical phage therapy as 
an alternative to current antibiotics.
There has been increasing interest in the development of 
substances with antipathogenic (or anti- virulence) properties 
in both healthcare- associated and industrial settings which, 
by definition, do not kill bacterial pathogens but instead act to 
reduce damage to both products and human health [82–86]. 
In combination with antibiotics, these substances may offer 
an alternative way to reduce the morbidity associated with 
P. aeruginosa keratitis. By investigating antipathogenic treat-
ments, focus can be shifted away from the struggle to develop 
new and effective ways to kill bacteria and can instead focus on 
reducing harm by any means possible. Some such treatments 
under development target the inflammasomes of the immune 
system, which play an important role in inflammation of the 
eye during infection, leading to destruction of tissue [87]. In 
particular, nod- like receptors (NLR) P1, NLRP3, NLRC4 and 
the AIM2 (absent in melanoma 2) protein have been shown 
to play a role in increased severity in eye diseases. NLRP3 
generally plays a protective role in fighting infection in other 
parts of the body, particularly during lung infection, but in 
the eye it acts to recruit cytokines and chemokines, which 
increase inflammation [87]. Drugs that inhibit caspase-1 have 
been used as an effective adjuvant therapy in a mouse model 
of keratitis infection to reduce disease severity. Caspase-1 acts 
to cleave prointerleukin-1β (IL-1β) and prointerleukin-18 
(IL-18) to their active forms, which go on to contribute to 
inflammation. A caspase-1 inhibitor can be effectively used 
as an adjuvant therapy alongside ciprofloxacin to reduce the 
severity of corneal inflammation during infection, as well as 
a significant reduction in recruitment of PMNs. Mice in this 
study were also infected with a ciprofloxacin- resistant strain 
of P. aeruginosa and improved clinical scores were observed 
following treatment with the caspase-1 inhibitor and cipro-
floxacin combined treatment [88].
The antipathogenic effects of essential oils are also of interest, 
commonly derived from foodstuffs, and their effects on QS 
systems and biofilm formation. The non- volatile essential oil 
6- Gingerol, derived from ginger root, has been reported to have 
anti- QS and anti- biofilm effects comparable to the synthetic 
compound furanone C-30 against P. aeruginosa, as well as anti- 
cancer, anti- inflammatory and analgesic effects in humans [82]. 
Flavonoids are naturally produced plant metabolites that have 
been shown to reduce P. aeruginosa biofilm formation by inhibi-
tion of the LasR QS system [85]. The molecules act by binding 
to the LasR ligand binding domain and preventing binding of 
the protein to DNA. In vivo the flavonoids were shown to inhibit 
transcription of rhlA and reduce pyocyanin production [86]. 
Whilst antipathogenic substances are unlikely to offer a single 
solution to the problem of antibiotic resistance, there is potential 
for development of antipathogenic substances as adjuvants to 
antibiotic treatment, both to reduce morbidity to patients and 
reduce the burden of antibiotic resistance on healthcare systems 
worldwide.
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